MARKETS

BSE Prices delayed by 5 minutes... Prices as on Apr 19, 2018   ABB India 1249 [ -0.61% ]ACC 1574.25 [ 0.07% ]Ambuja Cements Ltd. 247.25 [ 1.00% ]Asian Paints Ltd. 1166.8 [ -0.38% ]Axis Bank Ltd. 513.5 [ -1.00% ]Bajaj Auto Ltd. 2855.1 [ -0.26% ]Bank of Baroda 145.05 [ 2.22% ]Bharti Airtel 394.95 [ 2.64% ]Bharat Heavy Ele 88.25 [ 0.68% ]Bharat Petroleum 377.55 [ -6.81% ]Britannia Ind. 5391.4 [ 0.59% ]Cairn India Ltd. 285.4 [ 0.90% ]Cipla 584.2 [ 0.06% ]Coal India Ltd. 282.85 [ -0.77% ]Colgate Palm. 1110.45 [ 0.50% ]Dabur India 357.25 [ 0.55% ]DLF Ltd. 214.85 [ 1.27% ]Dr. Reddy's Labs 2130.4 [ 1.60% ]GAIL (India) Ltd. 335.2 [ 1.53% ]Grasim Inds. 1104 [ 0.93% ]HCL Technologies 1015.45 [ 1.67% ]HDFC 1864.45 [ -0.65% ]HDFC Bank 1941.95 [ 0.25% ]Hero MotoCorp 3729.25 [ -0.34% ]Hindustan Unilever L 1454.25 [ 0.20% ]Hindalco Indus. 264.75 [ 9.13% ]ICICI Bank 289.15 [ -0.36% ]IDFC L 53.6 [ 1.04% ]Indian Hotels Co 149.05 [ -2.13% ]IndusInd Bank 1834.1 [ -0.57% ]Infosys 1132.7 [ 0.64% ]ITC Ltd. 277 [ 0.62% ]Jindal St & Pwr 260.1 [ 4.04% ]Kotak Mahindra Bank 1155.2 [ -0.24% ]L&T 1384.3 [ 1.74% ]Lupin Ltd. 790.1 [ -0.06% ]Mahi. & Mahi 803.1 [ 0.48% ]Maruti Suzuki India 9076.55 [ -0.51% ]MTNL 20.2 [ -0.98% ]Nestle India 9153.5 [ 1.85% ]NIIT Ltd. 104.75 [ 1.65% ]NMDC Ltd. 125.05 [ 1.75% ]NTPC 177.45 [ -0.48% ]ONGC 183.15 [ 0.74% ]Punj. NationlBak 96.1 [ -1.18% ]Power Grid Corpo 208.2 [ 1.61% ]Reliance Inds. 941.25 [ 0.45% ]SBI 246.25 [ 0.00% ]Vedanta 311.7 [ 6.69% ]Shipping Corpn. 76.55 [ 11.75% ]Sun Pharma. 508.8 [ -0.61% ]Tata Chemicals 739.2 [ 0.61% ]Tata Global Beverage 286.1 [ 0.77% ]Tata Motors Ltd. 334.85 [ -0.19% ]Tata Steel 620.55 [ 3.17% ]Tata Power Co. 86.9 [ -0.86% ]Tata Consultancy 3190.65 [ 0.99% ]Tech Mahindra Ltd. 665.3 [ 1.36% ]UltraTech Cement 4100.4 [ 2.58% ]United Spirits 3480.65 [ 1.69% ]Wipro Ltd 291.6 [ -0.38% ]Zee Entertainment En 591.75 [ 0.71% ]

News Details

You can view in detail.
Indian Pharma exports to USA may go up in 2017-18: Report 17/07/2017 17:13

Despite pricing pressure and stiff competition, the Indian Pharma exports to the USA may go up in 2017-18 as USD 50 billion worth of drugs are expected to become off-patented during the current year giving hope to boost export market, said a report by Care Ratings as per the PTI.

"The Indian pharmaceutical industry is likely to face competition from other countries to get ANDA (Abbreviated New Drug Application) approval. Apart from this, the Indian pharma companies will continue to witness pricing pressure in the US generics market due to consolidation of distribution channels and increase in competition.

"The pharma export volumes from India to US however are expected to rise. This will be backed by about USD 55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," the Care report said.

The Indian Pharmaceuticals Industry (IPI) earns around 70 per cent of its revenues from sale of generic drugs and generates around 50 per cent of its revenues from exports.

IPI registered revenue of around USD 33 billion in 2016. Exports form a major part of the industry's turnover and over 50 per cent of the sales comes from exports.

Of the total exports of USD 16.8 billion during the year 2016-17, majority of the exports, accounting for 40.6 per cent were to the American continent followed by 19.7 per cent to Europe, 19.1 per cent to Africa and 18.8 per cent within Asia, the report said.

"The prime reasons for the weak exports were price erosion in the generic market in the USA due to consolidation among customers i.E. The distribution channels, increase in competition, absence of blockbuster drugs going off patent and regulatory issues faced by Indian pharma companies," it said.

In 2015-16, exports to USA surged by 27.8 per cent to USD 5.5 billion on a year-on-year basis. However, the export scenario to USA weakened and it grew by a marginal 1.3 per cent to USD 5.6 billion in 2016-17.

In 2016-17, the industry faced a slew of issues with increased scrutiny of regulatory authorities, increase in competition in generics market of one of its primary export destination, USA. This, in turn, resulted in marginal growth in exports to that country.

Also, stricter enforcement of Drug Price Control Order has impacted revenue growth rate of the industry in domestic market, the report said.

The report also said with implementation of GST, there will be no major change in the prices of medicines and there is an expectation that the government will continue to keep a check on the prices of controlled as well as non-controlled drugs.

LOAD MORE